A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
Aggregate royalty for cellular SEPs in recent court decisions
This academic paper, “Aggregate Royalty for Cellular SEPs in Recent Court Decisions,” published in GRUR Patent by CRA Competition experts Nadia Soboleva and...